Celldex Therapeutics (CLDX)

• Market cap: $1.12B
• 1 day: -7.05%
• 5 days: -15.82%
• 1 month: -12.82%
• 3 months: -34.59%
• 6 months: -47.93%
• Year to date: -34.59%
• 1 year: -59.49%
• 5 years: 947.83%
• 10 years: -95.82%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Employees: 186

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

33% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 49

2.67% more ownership

Funds ownership: 108.4% [Q3] → 111.07% (+2.67%) [Q4]

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 [Q3] → 174 (-2) [Q4]

24% less capital invested

Capital invested by funds: $2.44B [Q3] → $1.86B (-$581M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $36 113% upside
• Avg. target: $55 224% upside
• High target: $80 374% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Morgan Stanley Judah Frommer 36% 1-year accuracy 4 / 11 met price target	173% upside $46	Overweight Initiated	20 Mar 2025
Goldman Sachs Richard Law 60% 1-year accuracy 6 / 10 met price target	113% upside $36	Neutral Maintained	3 Mar 2025
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 85 / 422 met price target	374% upside $80	Buy Reiterated	3 Mar 2025
UBS Trung Huynh 50% 1-year accuracy 4 / 8 met price target	161% upside $44	Buy Initiated	13 Feb 2025
Cantor Fitzgerald Kristen Kluska 30% 1-year accuracy 32 / 108 met price target	297% upside $67	Overweight Reiterated	29 Jan 2025